Cargando…
Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702”
BACKGROUND: Carbon ion Radiotherapy for prostate cancer is widely used, however reports are limited from single institute or short follow up. We performed a prospective observational study (GUNMA0702) to evaluate the feasibility and efficacy of carbon ion radiotherapy for localized and locally advan...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990498/ https://www.ncbi.nlm.nih.gov/pubmed/32000716 http://dx.doi.org/10.1186/s12885-020-6570-8 |
_version_ | 1783492513009500160 |
---|---|
author | Kawamura, Hidemasa Kubo, Nobuteru Sato, Hiro Mizukami, Tatsuji Katoh, Hiroyuki Ishikawa, Hitoshi Ohno, Tatsuya Matsui, Hiroshi Ito, Kazuto Suzuki, Kazuhiro Nakano, Takashi |
author_facet | Kawamura, Hidemasa Kubo, Nobuteru Sato, Hiro Mizukami, Tatsuji Katoh, Hiroyuki Ishikawa, Hitoshi Ohno, Tatsuya Matsui, Hiroshi Ito, Kazuto Suzuki, Kazuhiro Nakano, Takashi |
author_sort | Kawamura, Hidemasa |
collection | PubMed |
description | BACKGROUND: Carbon ion Radiotherapy for prostate cancer is widely used, however reports are limited from single institute or short follow up. We performed a prospective observational study (GUNMA0702) to evaluate the feasibility and efficacy of carbon ion radiotherapy for localized and locally advanced prostate cancer. METHODS: Between June 2010 and August 2013, 304 patients with localized prostate cancer were treated, with a median follow-up duration of 60 months. All patients received carbon ion radiotherapy with 57.6 Gy (RBE) in 16 fractions over 4 weeks. Hormonal therapy was given according to the risk group. Toxicity was reported according to the Common Toxicity Criteria for Adverse Event, Version 4.0 by the National Cancer Institute. RESULTS: The overall 5-year biochemical relapse-free rate was 92.7%, with rates of 91.7, 93.4, and 92.0% in low-risk, intermediate-risk, and high-risk patients, respectively. The 5-year local control and overall survival rates were 98.4 and 96.6%, respectively. Acute grade 3 or greater toxicity was not observed. Late grade 2 and grade 3 genitourinary and gastrointestinal toxicity rates were 9 and 0.3%, and 0.3, and 0%, respectively. CONCLUSIONS: The present protocol of carbon ion radiotherapy for prostate cancer provided low genitourinary and gastrointestinal toxicity with good biochemical control within 5 years. TRIAL REGISTRATION: University Medical Information Network Clinical Trial Registry number: UMIN000003827. |
format | Online Article Text |
id | pubmed-6990498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69904982020-02-03 Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702” Kawamura, Hidemasa Kubo, Nobuteru Sato, Hiro Mizukami, Tatsuji Katoh, Hiroyuki Ishikawa, Hitoshi Ohno, Tatsuya Matsui, Hiroshi Ito, Kazuto Suzuki, Kazuhiro Nakano, Takashi BMC Cancer Research Article BACKGROUND: Carbon ion Radiotherapy for prostate cancer is widely used, however reports are limited from single institute or short follow up. We performed a prospective observational study (GUNMA0702) to evaluate the feasibility and efficacy of carbon ion radiotherapy for localized and locally advanced prostate cancer. METHODS: Between June 2010 and August 2013, 304 patients with localized prostate cancer were treated, with a median follow-up duration of 60 months. All patients received carbon ion radiotherapy with 57.6 Gy (RBE) in 16 fractions over 4 weeks. Hormonal therapy was given according to the risk group. Toxicity was reported according to the Common Toxicity Criteria for Adverse Event, Version 4.0 by the National Cancer Institute. RESULTS: The overall 5-year biochemical relapse-free rate was 92.7%, with rates of 91.7, 93.4, and 92.0% in low-risk, intermediate-risk, and high-risk patients, respectively. The 5-year local control and overall survival rates were 98.4 and 96.6%, respectively. Acute grade 3 or greater toxicity was not observed. Late grade 2 and grade 3 genitourinary and gastrointestinal toxicity rates were 9 and 0.3%, and 0.3, and 0%, respectively. CONCLUSIONS: The present protocol of carbon ion radiotherapy for prostate cancer provided low genitourinary and gastrointestinal toxicity with good biochemical control within 5 years. TRIAL REGISTRATION: University Medical Information Network Clinical Trial Registry number: UMIN000003827. BioMed Central 2020-01-30 /pmc/articles/PMC6990498/ /pubmed/32000716 http://dx.doi.org/10.1186/s12885-020-6570-8 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Kawamura, Hidemasa Kubo, Nobuteru Sato, Hiro Mizukami, Tatsuji Katoh, Hiroyuki Ishikawa, Hitoshi Ohno, Tatsuya Matsui, Hiroshi Ito, Kazuto Suzuki, Kazuhiro Nakano, Takashi Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702” |
title | Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702” |
title_full | Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702” |
title_fullStr | Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702” |
title_full_unstemmed | Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702” |
title_short | Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702” |
title_sort | moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “gunma0702” |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990498/ https://www.ncbi.nlm.nih.gov/pubmed/32000716 http://dx.doi.org/10.1186/s12885-020-6570-8 |
work_keys_str_mv | AT kawamurahidemasa moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702 AT kubonobuteru moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702 AT satohiro moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702 AT mizukamitatsuji moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702 AT katohhiroyuki moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702 AT ishikawahitoshi moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702 AT ohnotatsuya moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702 AT matsuihiroshi moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702 AT itokazuto moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702 AT suzukikazuhiro moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702 AT nakanotakashi moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702 AT moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702 |